Last fall, Tzield was approved to delay type 1 diabetes in people predicted to develop it. This week, I’m talking one of the first families to use what used to be called Teplizumab for their son, as a regular patient, outside the clinical trials. How exactly does this all work? Who’s eligible and how do you cover the enormous financial cost?
Amanda Troutman talks about why they went through this process with her son, William. Their whole family was tested for the genetic markers after their daughter, Jenna, was diagnosed in 2020.
As always, this podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Our previous episodes on Tzield: https://diabetes-connections.com/?s=teplizumab
More about the Troutman family: https://www.vcuhealth.org/news/north-carolina-teen-among-first-in-us-to-receive-new-diabetes-drug
Please visit our Sponsors & Partners – they help make the show possible!
Check out VIVI Cap to protect your insulin from extreme temperatures
Learn more about AG1 from Athletic Greens
Drive research that matters through the T1D Exchange
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here’s where to find us:
Learn more about everything at our home page www.diabetes-connections.com
Reach out with questions or comments: firstname.lastname@example.org